JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective [0.03%]
JAK抑制剂在髓系肿瘤中的应用：理论依据、现有数据和未来前景
A Tefferi,A Pardanani
A Tefferi
JAK-STAT is an appealing but also problematic drug target in BCR-ABL1-negative myeloproliferative neoplasms (MPN) - it is appealing because the majority of patients with MPN harbor gain-of-function JAK2 or MPL mutations - it is problematic ...
Acute myeloid leukemia with mutated nucleophosmin (NPM1): any hope for a targeted therapy? [0.03%]
携带核仁磷酸蛋白(NPM1)突变的急性髓系白血病患者靶向治疗的希望何在？
Brunangelo Falini,Ilaria Gionfriddo,Federica Cecchetti et al.
Brunangelo Falini et al.
Acute myeloid leukemia (AML) carrying nucleophosmin (NPM1) mutations displays distinct molecular and clinical-pathological features that led to its inclusion as provisional entity in 2008 WHO classification of myeloid neoplasms. Since NPM1 ...
Dimitris Tousoulis,Nikolaos Papageorgiou,Emmanuel Androulakis et al.
Dimitris Tousoulis et al.
Several prospective epidemiological studies and clinical observations provided evidence regarding fibrinogen and coronary artery disease (CAD). Many of these studies firmly correlate fibrinogen with CAD. However, it is uncertain whether thi...
Koen van Besien
Koen van Besien
Allogeneic transplantation is established as a curative treatment for follicular lymphoma, but with considerable short and long-term morbidity and mortality. Data and controversies regarding conditioning regimen, donor source, GVHD prophyla...
Arijit Biswas,Vytautas Ivaskevicius,Rainer Seitz et al.
Arijit Biswas et al.
Mutational reports over the past two decades have accumulated an immense amount of literature for inherited Factor XIII deficiency. However, the genotype and phenotype correlations for inherited Factor XIII deficiency are complicated. While...
Emerging options in the treatment of deep vein thrombosis and pulmonary embolism [0.03%]
深静脉血栓形成和肺栓塞治疗的新进展
Benjamin Brenner,Ron Hoffman
Benjamin Brenner
The incidence of venous thromboembolism (VTE), including deep vein thrombosis and pulmonary embolism, is increasing and the disease has been found to account for over 500,000 annual deaths in the European Union. VTE is associated with incre...
Barbara J Bain
Barbara J Bain
Diagnosis of haemoglobinopathies, including thalassaemias, can result from either a clinical suspicion of a disorder of globin chain synthesis or from follow-up of an abnormality detected during screening. Screening may be carried out as pa...
Akram Da&#x;dara,Patrick J Skelly
Akram Da&#x;dara
Schistosomes (blood flukes) are long lived, intravascular parasites that afflict ~200 million people worldwide. Here we review the potential ability of these parasites to exert control on local vascular physiology. We examine schistosome ka...
Catherine P M Hayward
Catherine P M Hayward
Platelet function disorders are inherited and acquired conditions that represent a common cause of bleeding. Their clinical findings are generally similar to von Willebrand disease. It is often challenging to diagnose common platelet functi...
Practical management of adverse events in multiple myeloma: can therapy be attenuated in older patients? [0.03%]
多发性骨髓瘤不良反应的管理及老年患者的治疗强度减少问题
Antonio Palumbo,Maria-Victoria Mateos,Sara Bringhen et al.
Antonio Palumbo et al.
The current standard of care for elderly patients with newly diagnosed multiple myeloma is melphalan and prednisone (MP) in combination with either bortezomib (VMP) or thalidomide (MPT), with lenalidomide plus dexamethasone increasingly bei...